Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients

REFERENCES

• Sarnak MJ, Levey AS, Schoolwerth AC, Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108:2154–2169.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Covic A, Chazot C, Leunissen K, Luño J, Yaqoob M. Accorde Programme. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant. 2004;19(5):1058–1068.
   PubMedGoogle Scholar
• Eknoyan G. Cardiovascular mortality and morbidity in dialysis patients. Mineral Electrolyte Metab. 1999;25:100–104.
   PubMedGoogle Scholar
• Locatelli F, Marcelli D, Conte F, Cardiovascular disease in chronic renal failure: The challenge continues. Nephrol Dial Transplant. 2000;15(Suppl. 5):69–80.
   PubMedGoogle Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(Suppl. 3):S112–S119.
   PubMed Web of Science ®Google Scholar
• Zimmerman J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658.
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Gonzales EC, Wang J, Said S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis. 1994;23: 828–834.
   PubMed Web of Science ®Google Scholar
• Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(Suppl. 12):S24–S30.
   Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;131:607–617.
   Google Scholar
• Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis. 2000;35:1226–1237.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Amann K, Ketteler M. Cardiovascular disease in chronic kidney disease. In: Feehally J, Floege J, Johnson RJ, eds. Comprehensive Clinical Nephrology. 3rd ed., Philadelphia: Mosby Elsevier; 2007:839–852.
   Google Scholar
• Liu J, Rosner MH. Lipid abnormalities associated with end-stage renal disease. Semin Dial. 2006;19:32–40.
   PubMed Web of Science ®Google Scholar
• Sarah SP. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol. 2003;14:S315–S320.
   Google Scholar
• Charles R, Terry A. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384.
   PubMedGoogle Scholar
• Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin J Am Soc Nephrol. 2006;1: 182–192.
   PubMedGoogle Scholar
• Kris-Etherton PM, Taylor DS, Yu-Poth S, Polyunsaturated fatty acids in the food chain in the united states. Am J Clin Nutr. 2000;71:179S–188S.
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenzanell' Infarto Miocardio. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-prevenzione trial. Lancet. 1999;354:447–455.
   PubMedGoogle Scholar
• Harris WS. N-3 fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr. 1997;65:S1645–S1654.
   PubMed Web of Science ®Google Scholar
• Dobell E, Chan M, Williams P, Allman M. Food preferences and food habits of patients with chronic renal failure undergoing dialysis. J Am Diet Assoc. 1993;93:1129–1135.
   PubMedGoogle Scholar
• Das UN. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essent Fatty Acids. 2001;65(1):37–40.
   PubMedGoogle Scholar
• Nakamura N, Hamazaki T, Jokaji H, Minami S, Kobayashi M. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res. 1998;28(3):192–195.
   PubMedGoogle Scholar
• Grimsgaard S, Bonaa KH, Hansen JB, Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997; 66(3):649–659.
   PubMed Web of Science ®Google Scholar
• Kelley DS, Siegel D, Fedor DM, Adkins Y, Mackey BE. DHA supplementation decreases serum C-reactive protein and other markers of inflammatory in hypertriglyceridemic men. J Nutr. 2009;139:495–501.
   PubMed Web of Science ®Google Scholar
• Stirban A, Nandrean S, Götting C, Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr. 2010;91:808–813.
   PubMed Web of Science ®Google Scholar
• Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391–409.
   PubMedGoogle Scholar
• Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006; 98(4A): 27i–33i.
   PubMed Web of Science ®Google Scholar
• Khan S, Minihane AM, Talmud PJ, Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002;43(6):979–985.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki KC, Bays HE, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol. 2009;3(5):442–340.
   Google Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387–393.
   PubMed Web of Science ®Google Scholar